| Iupac Name: | 2-2-fluoro-4-(3-methoxyphenyl)phenylcarbamoyl]cyclopentene-1-carboxylic acid| C=20 | H=18 | F=1 | N=1 | O=4| SMILES = COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)O)F| StdInChI = 1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)| StdInChIKey = XPRDUGXOWVXZLL-UHFFFAOYSA-N}}Vidofludimus is an investigational new drug that is being evaluated to treat Crohn's disease and ulcerative colitis.[1] It is a dihydroorotate dehydrogenase inhibitor.[2] References
|
